UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease

What To Know

Teva and Sanofi presented Phase 2b long-term extension (RELIEVE UCCD, NCT05668013) data at UEG Week showing investigational antibody duvakitug (anti-TL1A) maintained clinical and endoscopic improvements through 44 weeks in patients with moderately-to-severely active ulcerative colitis and Crohn’s disease who responded to induction.

Reported endpoints included clinical remission and response (modified Mayo Score for UC; CDAI for CD) and endoscopic improvement/response (Mayo Endoscopic Score for UC; SES-CD for CD). Two maintenance doses (450 mg and 900 mg subcutaneously every 4 weeks) were evaluated and efficacy was numerically higher at 900 mg.

Duvakitug was generally well tolerated over the maintenance period with no new safety signals versus induction; most common events were upper respiratory infections and nasopharyngitis. The press release also noted biomarker analyses shared at the meeting that relate to inflammation and tissue remodeling.

The report is a company press release summarizing data presented at a conference; it describes descriptive efficacy rates and confidence intervals but does not provide full peer-reviewed results or detailed safety tables.